Ask AI
ProCE Banner Series

Optimizing Frontline Treatment of DLBCL: An Expert Roundtable on the Emerging Role of BTK Inhibitor–Based Therapies

Join us for this live symposium in conjunction with EHA2026 in which an expert panel will discuss efficacy of current standards of care in the frontline management of patients with DLBCL, the greatest unmet clinical needs in the frontline setting, rationale for targeting BTK in untreated DLBCL, emerging efficacy and safety of BTKi-based treatments in the frontline DLBCL setting, and ongoing investigations of BTKi-based therapies for patients who are newly diagnosed with DLBCL.

Please note: You must be registered for the EHA2026 Congress to attend this symposium. You may register at: https://ehaweb.org/connect-network/eha2026-congress/eha2026-registration

  AMA
Who Should Attend

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with DLBCL.

All Events

Optimizing Frontline Treatment of DLBCL: An Expert Roundtable on the Emerging Role of BTK Inhibitor–Based Therapies

Upcoming Events

June

12

2026

7:30 AM - 9:30 AM Eastern Time (ET)

In-person

Stockholmsmässan, Massvagen 1, 125 30 Alvsjö, Sweden

8:00 AM - 9:30 AM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge, confidence, and competence in optimizing frontline treatment of patients with DLBCL. 

Target Audience
This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with DLBCL. 

Learning Objectives
Upon completion of this event, participants should be able to:

  • Educate colleagues and patients on the mechanisms of action and rationales for using novel BTK inhibitor–based therapies in the frontline setting of DLBCL
  • Evaluate the potential clinical application of emerging evidence for novel frontline BTK inhibitor–based therapies in DLBCL
  • Recommend the optimal frontline BTK inhibitor–based treatment for each patient with DLBCL, considering subtype, comorbidities, expert recommendations, and available evidence
  • Identify patients with DLBCL who are eligible for clinical trials evaluating novel frontline BTK inhibitor–based therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191